This is a working overview of anti-doping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Methocinnamox (MCAM) is an opioid receptor antagonist. It is a pseudo-irreversible non-competitive antagonist of the μ-opioid receptor and a competitive antagonist of the κ- and δ-opioid receptors. The drug has a very long duration of action of up to months with a single dose due to its pseudo-irreversibility. It is administered in animals by intravenous or subcutaneous injection. It was first described in the scientific literature in 2000. It has not been studied in humans as of 2022. There is interest in methocinnamox in the potential treatment of opioid use disorder and opioid overdose due to its much longer-lasting and insurmountable effects relative to other opioid antagonists like naloxone and naltrexone. Clinical trials of the drug are expected. Methocinnamox should not be confused with methoclocinnamox (MCCAM), which is a closely related but structurally different compound (chlorine instead of methyl on one of the benzene rings). The drug was derived via structural modification of buprenorphine.
In 1903, entrepreneur Ernest Woodruff merged three cold storage warehouses to form Atlanta Ice and Coal Company and in 1909 renamed the company Atlantic Ice and Coal as part of a large consolidation of ice and coal companies throughout the eastern states. In 1919, Woodruff bought the Coca-Cola Company from Asa Candler's children for $25,000,000. In 1935, Atlantic Ice & Coal Company changed names to Atlantic Company and began to expand into a variety of different businesses, including cold storage and beer production, the latter contributing up to 50% of the company's revenues at its peak. Atlantic Company diversified into ice convenience store development under the name EZ stores, before household refrigerators were commonplace. It also ran a fast food operation called Wishbone Fried Chicken. Atlantic Company merged with Munford Do it Yourself stores and became Atlantic-Munford, rapidly developing its convenience store growth. The company then merged with Jackson Minit Market and Handy Andy, and was renamed Jackson Atlantic, growing to 40 warehouses in the USA. It was one of the largest warehouse networks at that time. The company went public in 1968 and a few years later merged with United Refrigerated Services. The company then set out to develop the USA's most comprehensive cold storage network. Atlanta became the company's home again in the early 1980s. Acquisitions and mergers continued during the 1980s and 1990s with the company's current name, Americold, appearing in 1997.
Highly refractory woods These woods are slow and difficult to dry if the final product is to be free from defects, particularly cracks and splits. Examples are heavy structural timbers with high density such as ironbark (Eucalyptus paniculata), blackbutt (E. pillularis), southern blue gum (E. globulus) and brush box (Lophostemon cofertus). They require considerable protection and care against rapid drying conditions for the best results. Moderately refractory woods These timbers show a moderate tendency to crack and split during seasoning. They can be seasoned free from defects with moderately rapid drying conditions (i.e. a maximum dry-bulb temperature of 85 °C can be used). Examples are Sydney blue gum (E. saligna) and other timbers of medium density, which are potentially suitable for furniture. Non-refractory woods These woods can be rapidly seasoned to be free from defects even by applying high temperatures (dry-bulb temperatures of more than 100 °C) in industrial kilns. If not dried rapidly, they may develop discolouration (blue stain) and mould on the surface. Examples are softwoods and low density timbers such as Pinus radiata.
Sources: en.wikipedia.org
== Chemistry == The major chemical components from the pods are vanillin, vanillic acid, 4-hydroxybenzaldehyde and 4-hydroxybenzoic acid. Vanillin makes up 80% of the total aromatic compounds found in the pods, in contrast to the 50% content of Vanilla × tahitensis pods. Some of the other chemicals found in lesser amounts in the pods of Vanilla planifolia such as guaiacol, 4-methylguaiacol, acetovanilone, and vanillic alcohol also contribute to the perception of a vanilla flavor.Vanilla planifolia is notable for its role in vanilla production. The enzyme β-glucosidase is crucial in the release of vanillin during the curing process, which is essential for producing high-quality vanilla flavor.
===== Tourism development ===== Paetongtarn Shinawatra has designated tourism as the primary engine for Thailand's economic growth, taking a hands-on role in policy-making and international promotion. Her administration's strategy focuses on elevating Thailand's global image, enhancing tourist safety, and boosting revenue by attracting high-value visitors and establishing the nation as a year-round destination. A key initiative under her leadership is the "Amazing Thailand Grand Tourism and Sports Year 2025", a year-long campaign of festivals and major sporting events designed to attract visitors. This campaign is part of the broader "Ignite Thailand" vision, which aims to establish the country as a global hub for tourism and other key industries. In early 2025, she personally promoted this vision at international travel forums, such as ITB Berlin, setting an ambitious target of attracting 39 million tourists and generating 3.5 trillion baht in revenue for the year. As of early June 2025, Thailand had welcomed over 15 million international visitors for the year, showing a strong recovery. However, some economic research centers have noted that the ambitious full-year targets may face challenges due to a global economic slowdown and increasing regional competition.
Carnexiv is indicated for short-term treatment of up to seven days for partial seizures with complex symptomatology, generalized tonic–clonic seizures and mixed seizure patterns, in patients who are temporarily unable to take or tolerate oral medications. It has also been shown to improve symptoms of "typewriter tinnitus", a type of tinnitus caused by the neurovascular compression of the cochleovestibular nerve.
Sources: en.wikipedia.org
== Interactions with other treatments == Since the kidney is also an important excretory organ for numerous drugs, chronic kidney disease must be taken into account in the drug therapy of other diseases. For example, the plasma half-life may be significantly prolonged (e.g. with numerous antibiotics) and the dose must be reduced accordingly. Drugs that can only be administered with caution in cats with kidney disease include atenolol, carbimazole, chlorothiazide, digoxin and thiamazole.
The Journal of Pharmacy Practice is a bimonthly peer-reviewed healthcare journal that covers the field of pharmacy, including new drugs and therapies, pharmacokinetics, drug administration, and adverse drug reactions. The editor-in-chief is Michael Liu (Touro College of Pharmacy). It was established in 1988 and is currently published by SAGE Publications.
In physics, atomic spectroscopy is the study of the electromagnetic radiation absorbed and emitted by atoms. Since unique elements have unique emission spectra, atomic spectroscopy is applied for determination of elemental compositions. It can be divided by atomization source or by the type of spectroscopy used. In the latter case, the main division is between optical and mass spectrometry. Mass spectrometry generally provides significantly better analytical performance but is also significantly more complex. This complexity translates into higher purchase costs, higher operational costs, more operator training, and a greater number of components that can potentially fail. Because optical spectroscopy is often less expensive and has performance adequate for many tasks, it is far more common. Atomic absorption spectrometers are one of the most commonly sold and used analytical devices.
== Pharmacology == Chlordiazepoxide acts on benzodiazepine allosteric sites that are part of the GABAA receptor/ion-channel complex and this results in an increased binding of the inhibitory neurotransmitter GABA to the GABAA receptor thereby producing inhibitory effects on the central nervous system and body similar to the effects of other benzodiazepines. Chlordiazepoxide is an anticonvulsant. Chlordiazepoxide is preferentially stored in some organs including the hearts of neonates. Absorption by any administered route and the risk of accumulation is significantly higher in neonates. The withdrawal of chlordiazepoxide during pregnancy and breast feeding is recommended, as chlordiazepoxide rapidly crosses the placenta and also is excreted in breast milk. Chlordiazepoxide also decreases prolactin release in rats. Benzodiazepines act via micromolar benzodiazepine binding sites as Ca2+ channel blockers and significantly inhibit depolarization-sensitive Calcium uptake in animal nerve terminal preparations. Chlordiazepoxide inhibits acetylcholine release in mouse hippocampal synaptosomes in vivo. This has been found by measuring sodium-dependent high affinity choline uptake in vitro after pretreatment of the mice in vivo with chlordiazepoxide. This may play a role in chlordiazepoxide's anticonvulsant properties.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.